vedolizumab,rovalpituzumab tesirine,polatuzumab vedotin,rituximab,glofitamab,bortezomib
abbvie,takeda,roche
['fil,veral,12', 'dlbcl', 'rova,(-approval)', 'rova,(-approval),(-microvascular)', ' vedo', 'glofitamab', 'lymsm', 'polatuzumab', 'ritux']
congress | #ash22 max topp, shares results from the np40126 trial indicating that glofitamab can be safely combined with rchop as a fixed-duration treatment for patients with first line #dlbcl. #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm